Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
← catalyst calendarNCT07441395 · readout ≤ 315 d
Sponsored by Corvus Pharmaceuticals, Inc. (industry) · CRVS — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
200estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Feb 2026 | estimated | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
- Eczema, Atopic
Interventions
- Drug: Soquelitinib — also filed as CPI-818
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12
measured Baseline through Week 12
Permalink · CRVS's whole pipeline · Catalyst calendar · Every registered study · What changed